Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111097 | 1.00 | KYNU (0.62) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL1068619 | 1.00 | KYNU (0.62) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL806841 | 0.92 | SIRT2 (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL1110961 | 0.92 | SIRT2 (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL1110959 | 0.92 | SIRT2 (0.60) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL6059278 | 0.91 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL7215503 | 0.91 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL8386880 | 0.90 | SIRT2 (0.67) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL15613297 | 0.89 | CTSK (0.65) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL22161320 | 0.89 | CTSK (0.65) | KYNUALDH1A1ALOX15SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4516778-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119421876-A | Compounds and medicaments as DDR1 kinase inhibitors | 日本新药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024198077-A1 | AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR, AND METHOD FOR USING AMINO ACID DERIVATIVE AS INTERMEDIATE TO SYNTHESIZE L-GLUFOSINATE-AMMONIUM | 南京华狮新材料有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724766-A | Amino acid derivative, preparation method thereof and method for synthesizing L-glufosinate-ammonium as intermediate | 南京华狮新材料有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2010116328-A2 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | KYNU 2931/4885ALDH1A1 126/4885ALOX15 362/4885 |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | KYNU 1698/4885ALDH1A1 1854/4885ALOX15 334/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | KYNU 939/4885ALDH1A1 1129/4885ALOX15 3068/4885 |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | KYNU 2204/4885ALDH1A1 2364/4885ALOX15 3654/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | KYNU 3695/4885ALDH1A1 1828/4885ALOX15 2394/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | KYNU 3785/4885ALDH1A1 4517/4885ALOX15 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.